Evaluation of Daily CT Scans Using CT on Rails for Localization in the Treatment of Prostate Cancer
- Validate the software for CT-on-rails™ by comparing prostate target localization via
daily ultrasound vs computed tomography (CT) in patients undergoing radiotherapy for
- Determine the potential benefit of using fiducials in the prostate of patients
undergoing daily CT scans and/or ultrasounds for localization.
- Determine the intra- and inter-radiation treatment setup and target position
uncertainties, in terms of isocenter coordinates in space, using both the ultrasound
and CT scans compared to the coordinates of the isocenter determined at simulation, in
OUTLINE: This is a pilot study.
- Phase I: Patients undergo computed tomography (CT) using CT-on-rails™ twice weekly.
Patients undergo BAT™ ultrasound daily for prostate localization. Patients undergo
concurrent daily radiotherapy off study after imaging. After radiotherapy treatment is
complete, patients continue to undergo scanning using CT-on-rails™ twice weekly.
- Phase II: Patients undergo local anesthesia and surgical insertion of gold fiducial
markers into the prostate. After 1 week, patients undergo a daily CT scan using
CT-on-rails™ and bi-weekly BAT™ ultrasound. Patients undergo daily radiotherapy off
study after imaging. After radiotherapy treatment is complete, patients continue to
undergo scanning using CT-on-rails™ twice weekly.
PROJECTED ACCRUAL: A total of 40 patients (20 per study phase) will be accrued for this
Primary Purpose: Diagnostic
Validity of CT-on-rails software
Steven Feigenberg, MD
Fox Chase Cancer Center
United States: Federal Government
|Fox Chase Cancer Center - Philadelphia||Philadelphia, Pennsylvania 19111-2497|